Table 3 Grade 2–5 toxicity by maximum grade per patient (N=17)a
From: Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity
DL 4, 5A, 5B ( n =17) | Ovarian cancer ( n =19, all DLs) | |||||
|---|---|---|---|---|---|---|
Maximum toxicity grade (no. of patients) | Maximum toxicity grade (no. of patients) | |||||
G2 | G3 | G4 | G2 | G3 | G4 | |
Diarrhoea | 2 | 2 | 0 | 2 | 1 | 0 |
Fatigue | 2 | 1 | 0 | 4 | 2 | 0 |
Fistula | 1 | 0 | 0 | 2 | 0 | 0 |
Mucositisa | 3 | 2 | 0 | 0 | 0 | 0 |
Skin rashes | ||||||
HFSR | 8a | 0 | 0 | 17 | 0 | 0 |
Otherb | 2 | 0 | 0 | 0 | 0 | 0 |
Hypertension | 7 | 3 | 0 | 9 | 6 | 0 |
Perforation | 0 | 1 | 0 | 0 | 0 | 0 |
Proteinuria | 2 | 0 | 0 | 1 | 1 | 0 |
Thrombocytopaenia | 0 | 0 | 0 | 0 | 1 | 0 |
Thrombosis | 0 | 2 | 0 | 1 | 0 | 1 |
Transaminitis | 2 | 2 | 0 | 3 | 1 | 0 |
